Cell-free DNA and RNA - measurement and applications in clinical diagnostics with focus on metabolic disorders

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Cell-free DNA and RNA - measurement and applications in clinical diagnostics with focus on metabolic disorders. / Drag, Markus Hodal; Kilpeläinen, Tuomas Oskari.

In: Physiological Genomics, Vol. 53, No. 1, 2021, p. 33-46.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Drag, MH & Kilpeläinen, TO 2021, 'Cell-free DNA and RNA - measurement and applications in clinical diagnostics with focus on metabolic disorders', Physiological Genomics, vol. 53, no. 1, pp. 33-46. https://doi.org/10.1152/physiolgenomics.00086.2020

APA

Drag, M. H., & Kilpeläinen, T. O. (2021). Cell-free DNA and RNA - measurement and applications in clinical diagnostics with focus on metabolic disorders. Physiological Genomics, 53(1), 33-46. https://doi.org/10.1152/physiolgenomics.00086.2020

Vancouver

Drag MH, Kilpeläinen TO. Cell-free DNA and RNA - measurement and applications in clinical diagnostics with focus on metabolic disorders. Physiological Genomics. 2021;53(1):33-46. https://doi.org/10.1152/physiolgenomics.00086.2020

Author

Drag, Markus Hodal ; Kilpeläinen, Tuomas Oskari. / Cell-free DNA and RNA - measurement and applications in clinical diagnostics with focus on metabolic disorders. In: Physiological Genomics. 2021 ; Vol. 53, No. 1. pp. 33-46.

Bibtex

@article{73e93343e8204dacaf4b985c1f0488d4,
title = "Cell-free DNA and RNA - measurement and applications in clinical diagnostics with focus on metabolic disorders",
abstract = "Circulating cell-free DNA (cfDNA) and RNA (cfRNA) hold enormous potential as a new class of biomarkers for the development of non-invasive liquid biopsies in many diseases and conditions. In recent years, cfDNA and cfRNA have been studied intensely as tools for non-invasive prenatal testing, solid organ transplantation, cancer screening, and monitoring of tumors. In obesity, higher cfDNA concentration indicates accelerated cellular turnover of adipocytes during expansion of adipose mass and may be directly involved in the development of adipose tissue insulin resistance by inducing inflammation. Furthermore, cfDNA and cfRNA have promising diagnostic value in a range of obesity-related metabolic disorders, such as non-alcoholic fatty liver disease, type 2 diabetes, and diabetic complications. Here, we review the current and future applications of cfDNA and cfRNA within clinical diagnostics, discuss technical and analytical challenges in the field, and summarise the opportunities of using cfDNA and cfRNA in the diagnostics and prognostics of obesity-related metabolic disorders.",
author = "Drag, {Markus Hodal} and Kilpel{\"a}inen, {Tuomas Oskari}",
year = "2021",
doi = "10.1152/physiolgenomics.00086.2020",
language = "English",
volume = "53",
pages = "33--46",
journal = "Physiological Genomics",
issn = "1094-8341",
publisher = "American Physiological Society",
number = "1",

}

RIS

TY - JOUR

T1 - Cell-free DNA and RNA - measurement and applications in clinical diagnostics with focus on metabolic disorders

AU - Drag, Markus Hodal

AU - Kilpeläinen, Tuomas Oskari

PY - 2021

Y1 - 2021

N2 - Circulating cell-free DNA (cfDNA) and RNA (cfRNA) hold enormous potential as a new class of biomarkers for the development of non-invasive liquid biopsies in many diseases and conditions. In recent years, cfDNA and cfRNA have been studied intensely as tools for non-invasive prenatal testing, solid organ transplantation, cancer screening, and monitoring of tumors. In obesity, higher cfDNA concentration indicates accelerated cellular turnover of adipocytes during expansion of adipose mass and may be directly involved in the development of adipose tissue insulin resistance by inducing inflammation. Furthermore, cfDNA and cfRNA have promising diagnostic value in a range of obesity-related metabolic disorders, such as non-alcoholic fatty liver disease, type 2 diabetes, and diabetic complications. Here, we review the current and future applications of cfDNA and cfRNA within clinical diagnostics, discuss technical and analytical challenges in the field, and summarise the opportunities of using cfDNA and cfRNA in the diagnostics and prognostics of obesity-related metabolic disorders.

AB - Circulating cell-free DNA (cfDNA) and RNA (cfRNA) hold enormous potential as a new class of biomarkers for the development of non-invasive liquid biopsies in many diseases and conditions. In recent years, cfDNA and cfRNA have been studied intensely as tools for non-invasive prenatal testing, solid organ transplantation, cancer screening, and monitoring of tumors. In obesity, higher cfDNA concentration indicates accelerated cellular turnover of adipocytes during expansion of adipose mass and may be directly involved in the development of adipose tissue insulin resistance by inducing inflammation. Furthermore, cfDNA and cfRNA have promising diagnostic value in a range of obesity-related metabolic disorders, such as non-alcoholic fatty liver disease, type 2 diabetes, and diabetic complications. Here, we review the current and future applications of cfDNA and cfRNA within clinical diagnostics, discuss technical and analytical challenges in the field, and summarise the opportunities of using cfDNA and cfRNA in the diagnostics and prognostics of obesity-related metabolic disorders.

U2 - 10.1152/physiolgenomics.00086.2020

DO - 10.1152/physiolgenomics.00086.2020

M3 - Journal article

C2 - 33346689

VL - 53

SP - 33

EP - 46

JO - Physiological Genomics

JF - Physiological Genomics

SN - 1094-8341

IS - 1

ER -

ID: 253616440